Patients on edge as doctors prepare for hospital walkout
Junior doctors pull the trigger, stage walkout despite warning
[News Focus] Why do Korean doctors oppose having more physicians?
Health ministry orders all trainee doctors to keep providing medical treatment
Hyundai Motor, Supernal in search of best talents for advanced air mobility
Reality check: How diverse is Korea really? LGBTQ+ and society (9)
'Accommodating 2,000 new med students impossible': deans of med schools
Photo of RM with saxophone in military band goes viral
Police vow to probe doctors’ joint action
Govt. to fully allow telemedicine services in case of doctors' collective action: PM
FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to ClinicBy PRNEWSWIRE
Published : Oct. 26, 2023 - 00:10
- FDA INTERACT meeting reviews Turn Bio's ERA™ and eTurna™ technologies, approach and plans, paving way toward its IND
- Company continues to pace industry's cell regeneration therapy progress
MOUNTAIN VIEW, Calif., Oct. 25, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, received positive feedback during an FDA Initial Targeted Engagement for Regulatory Advice on CBER producTs (INTERACT) meeting to review progress and plans for its therapeutic treatment to rejuvenate skin cells.
The meeting focused on the path forward for TRN-001, which would be the first treatment to repair damaged skin at the cellular level, improving its integrity and reducing inflammation and cell senescence. The results of the INTERACT meeting mean that Turn Bio is well positioned to be the first company to take a cell rejuvenation therapy to clinical trials.
"We were gratified at the strong alignment between Turn Bio's approach to developing TRN-001 and the comments of FDA reviewers," said Anja Krammer, CEO of Turn Bio. "We look forward to advancing our pre-clinical work as we work toward IND submission."
TRN-001 was developed using Turn Bio's proprietary ERA™ technology, an mRNA-based platform designed to restore youthful function to cells. The therapy is delivered using the company's eTurna™ lipid particle carrier system, designed to effectively deliver and target drugs to specific tissue in the body.
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA-based ERA™ technology restores optimal gene expression by combatting the effects of aging in the epigenome. This restores cells' ability to prevent or treat disease and heal or regenerate tissue. It will help to fight incurable chronic diseases. Its eTurna™ Delivery Platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types.
The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see www.turn.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
email@example.com or (312) 543-9026
Junior doctors pull the trigger, stage walkout despite warnings
Ex-PM leaves Reform Party after rift with Lee Jun-seok
Putin's car gift to Kim showcases 'special' bond, defying UN sanctions